Sulfonamides

• 

  Subject Areas on Research

  • A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. 
  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance. 
  • A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. 
  • A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. 
  • A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 
  • A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. 
  • A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. 
  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. 
  • A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. 
  • A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. 
  • A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A reappraisal of loop diuretic choice in heart failure patients. 
  • A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. 
  • A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. 
  • AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT). 
  • AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation. 
  • Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. 
  • Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. 
  • Allergenic ingredients in nail polishes. 
  • Alpha1-adrenergic blockers and intraoperative floppy-iris syndrome. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. 
  • Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. 
  • Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. 
  • Anticoagulant therapy in unstable angina. 
  • Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII. 
  • Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. 
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. 
  • Argatroban for anticoagulation during cardiopulmonary bypass in an infant. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. 
  • Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. 
  • BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. 
  • Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. 
  • Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban. 
  • Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury. 
  • Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • COX-2-derived prostacyclin modulates vascular remodeling. 
  • CaMKII is essential for the proasthmatic effects of oxidation. 
  • Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells. 
  • Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression. 
  • Calmodulin-myosin light chain kinase inhibition changes fibroblast-populated collagen lattice contraction, cell migration, focal adhesion formation, and wound contraction. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Celecoxib (celebrex) increases canine lower esophageal sphincter pressure. 
  • Celecoxib does not delay cutaneous wound healing in haemophilia B mice. 
  • Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 
  • Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. 
  • Central corneal thickness. 
  • Changes in atrioventricular conduction properties with refractory-period modulation. 
  • Changes in calmodulin and its mRNA accompany reentry of quiescent (G0) cells into the cell cycle. 
  • Characterization of two labor-induced genes, DSCR1 and TCTE1L, in the pregnant ovine myometrium. 
  • Chronic thromboembolic pulmonary hypertension. 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. 
  • Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. 
  • Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Coenzyme Q10 and statins in heart failure: the dog that didn't bark. 
  • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. 
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. 
  • Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. 
  • Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit. 
  • Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. 
  • Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: effects of silencing CREB gene expression on Akt activation. 
  • Copper is required for oncogenic BRAF signalling and tumorigenesis. 
  • Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy. 
  • Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes. 
  • Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design. 
  • Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors 
  • Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat. 
  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. 
  • Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. 
  • Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. 
  • Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. 
  • Developmental neurotoxicity of perfluorinated chemicals modeled in vitro. 
  • Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. 
  • Direct thrombin inhibitors: alternatives to heparin. 
  • Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. 
  • Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Dofetilide dose reductions and discontinuations in women compared with men. 
  • Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieu makes a difference. 
  • Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias. 
  • Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor. 
  • Effect of pazopanib on tumor microenvironment and liposome delivery. 
  • Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. 
  • Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction. 
  • Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. 
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. 
  • Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. 
  • Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular function. 
  • Enantiomeric metabolic interactions and stereoselective human methadone metabolism. 
  • Endogenous ghrelin and 5-HT regulate interdigestive gastrointestinal contractions in conscious rats. 
  • Estimating data transformations in nonlinear mixed effects models. 
  • Evaluation of the dofetilide risk-management program. 
  • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. 
  • Flow cytometric analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor. 
  • Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. 
  • Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. 
  • Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂. 
  • HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. 
  • HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. 
  • Heparin-induced thrombocytopenia and cardiac surgery. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. 
  • Identification and inhibitory properties of a novel Ca(2+)/calmodulin antagonist. 
  • Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. 
  • Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • Increase in antibiotic resistance among isolates of Salmonella in the United States, 1967-1975. 
  • Induction of miR-132 and miR-212 Expression by Glucagon-Like Peptide 1 (GLP-1) in Rodent and Human Pancreatic β-Cells. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. 
  • Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. 
  • Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. 
  • Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. 
  • Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. 
  • Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • Intraoperative floppy iris syndrome: report of a case and histopathologic analysis. 
  • JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. 
  • Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. 
  • Key roles of necroptotic factors in promoting tumor growth. 
  • Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model. 
  • MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation. 
  • Management of glaucoma in pregnancy and lactation. 
  • Maximal beta3-adrenergic regulation of lipolysis involves Src and epidermal growth factor receptor-dependent ERK1/2 activation. 
  • Measuring carotid artery intima-media thickness: simplicity versus complexity? 
  • Medical Expulsive Therapy is Useful for Urinary Calculi. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. 
  • Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. 
  • Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Modulation of IA currents by capsaicin in rat trigeminal ganglion neurons. 
  • Monitoring direct thrombin inhibitors: time for standardization. 
  • Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. 
  • New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. 
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. 
  • New treatment options for heparin-induced thrombocytopenia. 
  • Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. 
  • Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. 
  • Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. 
  • Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 
  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 
  • Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3. 
  • Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. 
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). 
  • Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. 
  • Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. 
  • Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. 
  • Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. 
  • Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. 
  • Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. 
  • Phase I study of pazopanib plus TH-302 in advanced solid tumors. 
  • Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. 
  • Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'? 
  • Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair. 
  • Practitioner acceptance of the dofetilide risk-management program. 
  • Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). 
  • Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. 
  • Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor. 
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 
  • Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. 
  • Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. 
  • ROC curve estimation under test-result-dependent sampling. 
  • Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. 
  • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 
  • Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. 
  • Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. 
  • Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion. 
  • Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. 
  • Releasing the block: setting differentiation free with mutant IDH inhibitors. 
  • Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. 
  • Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. 
  • Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. 
  • Results of the FUEL Trial. 
  • SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials. 
  • Scanning electron microscopical observations of two novel hemostatic polymers. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. 
  • Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. 
  • Skin tight: macrophage-specific COX-2 induction links salt handling in kidney and skin. 
  • Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. 
  • Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. 
  • Stereochemistry and mechanism of the Brønsted acid catalyzed intramolecular hydrofunctionalization of an unactivated cyclic alkene. 
  • Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. 
  • Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC. 
  • Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus. 
  • Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. 
  • Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. 
  • Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. 
  • Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. 
  • Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation. 
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. 
  • Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. 
  • Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. 
  • TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension. 
  • Tamsulosin and the intraoperative floppy iris syndrome. 
  • Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. 
  • Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The STAMPEDE trial and celecoxib: how to adapt? 
  • The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. 
  • The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. 
  • The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. 
  • The polymodal ion channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and apoptosis of mouse retinal ganglion cells. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. 
  • The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation. 
  • Therapy of inflammatory bowel disease: what to expect in the next decade. 
  • Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. 
  • Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). 
  • Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. 
  • Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. 
  • Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. 
  • Treatment of pneumococcal meningitis with cephaloridine. 
  • Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. 
  • Upregulation of AKT1 protein expression in forskolin-stimulated macrophage: evidence from ChIP analysis that CREB binds to and activates the AKT1 promoter. 
  • Valdecoxib-associated acute generalized exanthematous pustulosis. 
  • Variability of action potential duration in pharmacologically induced long QT syndrome type 1. 
  • Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. 
  • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. 
  • Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. 
  • beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. 
  • beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
• 

  Keywords of People

  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Yan, Hai, Adjunct Professor of Pathology, Pathology